UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network

Cancer, 2020-01, Vol.126 (1), p.98-104

2020

Volltextzugriff (PDF)

Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study

Cancer, 2017-09, Vol.123 (17), p.3285-3290

2017

Volltextzugriff (PDF)

Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma

PloS one, 2013-02, Vol.8 (2), p.e57160-e57160

2013

Volltextzugriff (PDF)

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

BMC cancer, 2018-08, Vol.18 (1), p.790-7, Article 790

2018

Volltextzugriff (PDF)

Perioperative BRAF inhibitors in locally advanced stage III melanoma

Journal of surgical oncology, 2017-12, Vol.116 (7), p.856-861

2017

Volltextzugriff (PDF)

Selective Intra-Arterial Doxorubicin Eluting Microsphere Embolization for Desmoid Fibromatosis: A Combined Prospective and Retrospective Study

Cancers, 2022-10, Vol.14 (20), p.5045

2022

Volltextzugriff (PDF)

LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications

Cancers, 2020-03, Vol.12 (3), p.757

2020

Volltextzugriff (PDF)

412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A250-A251

2020

Volltextzugriff (PDF)

Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

Clinical cancer research, 2013-09, Vol.19 (17), p.4792-4800

2013

Volltextzugriff (PDF)

Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database

Acta oncologica, 2021-11, Vol.60 (11), p.1466-1471

2021

Volltextzugriff (PDF)

A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor

Expert opinion on drug safety, 2016-04, Vol.15 (4), p.571-578

2016

Volltextzugriff (PDF)

Ethics and execution of developing a 2nd wave COVID vaccine – Our interim phase I/II VSV-SARS-CoV2 vaccine experience

Vaccine, 2021-05, Vol.39 (21), p.2821-2823

2021

Volltextzugriff (PDF)

New Approaches to Managing Liposarcoma: Will Cold Steel Remain the Only Way to Heal?

Journal of oncology practice, 2016-03, Vol.12 (3), p.230-231

2016

Volltextzugriff (PDF)

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Cancer discovery, 2022-05, Vol.12 (5), p.1248-1265

2022

Volltextzugriff (PDF)

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up

Clinical microbiology and infection, 2023-07, Vol.29 (7), p.918-923

2023

Volltextzugriff (PDF)

IOeRT in retroperitoneal sarcoma: Towards more organ preservation with comparable oncological outcomes

Surgical oncology, 2023-06, Vol.48, p.101940-101940, Article 101940

2023

Volltextzugriff (PDF)

Corrigendum to “Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up” [Clin Microbiol Infect] 29 (7) (2023) 918–923

Clinical microbiology and infection, 2024-03, Vol.30 (3), p.409-413

2024

Volltextzugriff (PDF)

Resection of Recurrent Pelvic Soft Tissue Sarcoma: Is the Risk Worth the Reward?

The Journal of surgical research, 2023-03, Vol.283, p.914-922

2023

Volltextzugriff (PDF)

Adoptive transfer of tumor-infiltrating lymphocytes for melanoma: new players, old game

Immunotherapy, 2015-05, Vol.7 (5), p.477-479

2015

Volltextzugriff (PDF)

MO24-1 Phase I/IIa trial evaluating safety and clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in advanced solid tumors

Annals of oncology, 2021-07, Vol.32, p.S313-S313

2021

Volltextzugriff (PDF)

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines; randomized trial, 3 months follow-up

Clinical microbiology and infection, 2023-03

2023

Volltextzugriff (PDF)

A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme

Oncotarget, 2015-10, Vol.6 (30), p.28999-29015

2015

Volltextzugriff (PDF)

Targeted tumor profiling and actionable somatic variants in sarcoma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.11551-11551

2018

Volltextzugriff (PDF)

Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases

Clinical colorectal cancer, 2023-12, Vol.22 (4), p.442-449.e1

2023

Volltextzugriff (PDF)

Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy

Melanoma management, 2016-06, Vol.3 (2), p.137-147

2016

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network

Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study

Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

Perioperative BRAF inhibitors in locally advanced stage III melanoma

Selective Intra-Arterial Doxorubicin Eluting Microsphere Embolization for Desmoid Fibromatosis: A Combined Prospective and Retrospective Study

LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications

412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors

Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database

A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor

Ethics and execution of developing a 2nd wave COVID vaccine – Our interim phase I/II VSV-SARS-CoV2 vaccine experience

New Approaches to Managing Liposarcoma: Will Cold Steel Remain the Only Way to Heal?

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up

IOeRT in retroperitoneal sarcoma: Towards more organ preservation with comparable oncological outcomes

Corrigendum to “Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up” [Clin Microbiol Infect] 29 (7) (2023) 918–923

Resection of Recurrent Pelvic Soft Tissue Sarcoma: Is the Risk Worth the Reward?

Adoptive transfer of tumor-infiltrating lymphocytes for melanoma: new players, old game

MO24-1 Phase I/IIa trial evaluating safety and clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in advanced solid tumors

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines; randomized trial, 3 months follow-up

A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme

Targeted tumor profiling and actionable somatic variants in sarcoma

Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases

Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy

Suchergebnisse filtern